Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema

Next Previous
Search
Trial Profile

The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms ADAPT

    • Most Recent Events

    • 25 Nov 2019 Primary endpoint (SCORAD (objective eczema severity score) at the end of 24 weeks of treatment with anti-IgE or placebo.) has been met as per results published in the JAMA Pediatrics
    • 25 Nov 2019 Results published in the JAMA Pediatrics
    • 23 May 2017 Trial design was published in the Trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top